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Abstract
Enteral nutritional support has been used via tube feeding for dysphagic stroke patients. We performed long and short term trials to evaluate
the effects of commercial enteral nutritional supports on nutrition and health in stroke patients (mRS = 3~5) and quality of life in their caregivers.
For a long term study, we recruited chronic (≥1 yrs) stroke patients (n = 6) and administered them 6 cans/day (1,200 kcal) of the commercial 
enteral formula N for 6 months according to IRB-approved protocol. We collected peripheral blood at 0, 2, 4 and 6 months. For a short term 
study, we recruited acute (≤3 months) stroke patients (n = 12) and randomly administered them two different commercial enteral formulas, N or
J, for 2 weeks. We collected their blood at 0, 4, 7 and 14 day of the administration. Blood samples were analyzed to quantify 19 health and
nutritional biomarkers and an oxidative stress biomarker, malondialdehyde (MDA). In order to evaluate quality of life, we also obtained the sense
of competence questionnaire (SCQ) from all caregivers at ‘before’ and ‘after trials’. As results, the enteral formula, N, improved hemoglobin and
hematocrit levels in the long term trial and maintained most of biomarkers within normal ranges. The SCQ levels of caregivers were improved
in the long term treatment (P < 0.05). In a case of the short term study, both of enteral formulas were helpful to maintain nutritional status of
the patients. In addition, MDA levels were decreased in the acute patients following formula consumption (0.05 < P< 0.1). Most of health and nutrition
outcomes were not different, even though there is a big difference in price of the two products. Thus, we evaluate the formula N has equal nutritional
efficacy compared to the formula J. In addition, long term use of enteral formula N can be useful to health and nutrition of stroke patients, and 
the quality of life for their caregivers.
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Introduction7)
Stroke survivors often face serious swallowing difficulty, and 
it is reported that about 24.3-52.6% of stroke patients suffered 
dysphagia [1,2]. Thus, enteral nutritional supports have been used 
via tube feeding to those dysphagic stroke patients. However, 
only 37.8-43.8% showed adequate nutritional state in the stroke 
patients receiving enteral nutrition [3]. Dysphagia, inadequate 
diet intake, and increased energy requirements during recovery 
might increase the risk of malnutrition [4]. In addition, nutritional 
status influences length of hospital stay, complications, and 
mortality of stroke patients, thus, it is necessary to optimize 
nutrition management for the patients [5,6]. For the nutritional 
purpose, enteral nutrition showed some physiological advantages, 
fewer complications, and cost less than parenteral nutrition [7,8]. 
Moreover, recent studies revealed that enteral diet containing 
antioxidants had improved clinical outcomes [9]. 
On the other hand, quality of life in caregivers is an important 
issue, because caregiver-burden has been proved to affect 
patients' clinical outcome. For example, if the caregiver got 
stressed or depressed, rehabilitation of the patients was proved 
to be less successful [10]. If the caregivers were healthy and 
felt capable of providing the care, their care was proved to have 
positive effect on the recovery, rehabilitation and survival of 
patients [11,12]. 
Recently, various commercial enteral formulas are administered 
to many hospitalized or home patients. In addition, many stroke 
patients require enteral feeding for several years or their whole 
life. Thus, there are great concerns about long term use of enteral 
products. However, few studies have been performed to see long 
term effects of commercial enteral formulas. In a case of 
commercial formula N, it has been used over 10 years in Korea 
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Table 1. Formulation comparison between formula N and J
Enteral formula N Enteral formula J N > J
1) N<J
1)
Energy (kcal) 1,000.0 1,000.0
Protein (g) 40.0 46.3 ○
Total Carbohydrate (g) 145.0 141.2 ○
Total Dietary Fiber (g) 4.0 15.0 ◎
scFOS (g)
2) 0.0 6.7 ◎
Total Fat (g) 30.0 32.8 ○
Vitamin A (IU) 2,500.0 4,166.7 ○
Beta-Carotene (mg) 0.0 2.1 ◎
Vitamin D (IU) 200.0 333.3 ○
Vitamin E (IU) 10.0 37.5 ◎
Vitamin K (mcg) 75.0 66.7 ○
Vitamin C (mg) 140.0 250.0 ○
Folic Acid (μg) 400.0 500.0 ○
Thiamin, Vit B1 (mg) 1.3 1.9 ○
Riboflavin, Vit B2  (mg) 1.5 2.2 ○
Vitamin B6 (mg) 1.4 2.5 ○
Vitamin B12 ( μg) 2.4 7.5 ◎
Niacin (mg) 16.0 25.0 ○
Choline (mg) 900.0 500.0 ○
Biotin (μg) 30.0 375.0 ◎
Pantothenic Acid (mg) 5.0 12.5 ◎
Sodium (mg) 1,025.0 1,125.0 ○
Potassium (mg) 700.0 1,541.7 ◎
Chloride (mg) 0.0 1,250.0 ◎
Calcium (mg) 770.0 1,000.0 ○
Phosphorus (mg) 700.0 1,000.0 ○
Magnesium (mg) 340.0 333.3 ○
Iodine (mcg) 150.0 125.0 ○
Manganese (mg) 2.0 4.2 ◎
Copper (mg) 0.8 1.7 ◎
Zinc (mg) 12.0 19.2 ○
Iron (mg) 12.0 15.0 ○
Selenium (μg) 0.0 58.3 ◎
Chromium (μg) 0.0 100.0 ◎
Molybdenum (μg) 0.0 125.0 ◎
L-Carnitine (mg) 150.0 125.0 ○
Taurine (mg) 400.0 125.0 ◎
1) Comparison of nutrient composition between enteral formula N and J : ○, higher 
than  the  other;  ◎,  over  2  fold  higher  than  the  other
2) Short-chain  fructooligosaccharides
for dysphagic patients with good price, compared to other 
imported formulas. Therefore, we performed two separate studies, 
i.e. a long term trial to evaluate N’s effects on the patients’ health 
and nutritional status and their caregivers’ quality of life, and 
another short term trial to see equality between N and another 
expensive formula J. For these studies, we analyzed 19 health 
and nutritional biomarkers. Considering the stroke causes and 
progress, which are related to reactive oxygen species (ROS), 
we also analyzed an oxidative stress biomarker, malondialdehyde 
(MDA), and assessed effects of the formulas on stroke progress. 
Finally, we investigated SCQ levels among caregivers to evaluate 
the benefit of enteral products for caregiver burden.
Subjects and Methods
Study subjects
This study was approved by IRB at Seoul National University 
Bundang Hospital (SNUBH), Sookmyung Women's University, 
and Seoul Veterans Hospital. We recruited outpatients who were 
taken care of community nurses. For a long term study, inclusion 
was restricted to patients, who were more than 1 year after stroke 
onset and had been fed a commercial enteral formula N, at least 
600 kcal/day for more than 1 year. The subjects were provided 
enteral formula N (1,200 kcal/day) for 6 months. Previous food 
habits were allowed to avoid any kind of artificial effects during 
the experiment, if they did not exceed daily calorie requirement. 
Blood samples were collected before the trial and at 2, 4, and 
6 months after the trial. 
For a short term study, we recruited acute stroke patients within 
1-3 months after the onset of stroke. Twelve patients participated 
in the short term intervention. We randomly divided the 12 
subjects into two groups for administration of commercial enteral 
formula N or J (1,500-1,800 kcal/day due to calorie requirement). 
Formulations of the two commercial enteral formulas are 
described in the Table 1. Blood samples were collected before 
intervention and at 4, 7, and 14 day. To estimate individual daily 
calorie requirement, we used Harris-Benedict equation (HBE) for 
basic metabolic rate (BMR) and added activity factor to the BMR.
Questionnaires
Data of patients and caregivers were obtained from questionnaires 
including characteristics of patients and caregivers, and sense of 
competence questionnaire (SCQ). Following one interviewer’s 
instruction, caregivers filled out the same questionnaires at 
‘before’ and ‘after the trial’.
We modified Scholte op Reimer et al. [13]’s SCQ and our 
SCQ reflected caregivers’ perceived burden with 3 subscales in 
total 27 items (subscale 1, satisfaction with the impaired person 
as a recipient of care, 7 items; subscale 2, satisfaction with one’s 
own performance as a caregiver, 12 items; subscale 3, consequences 
of involvement in care for the caregiver’s personal life, 8 items). 
Each item was graded with 4-point rating scale (1, no burden; 
4, the highest burden): range of total score, 27 to 108.
Analysis of nutrition- and health-related biomarkers
For biochemical analyses, each subject donated 5-10 ml of 
peripheral blood after an overnight fast. Whole blood samples 
were prepared from blood anticoagulated with ethylene diamine 
tetra acetic acid (EDTA) tubes (BD vacutainer, Franklin Lakes, 
NJ, USA). Gently inverting the EDTA tubes 8-10 times 
immediately after collection, we stored them in a refrigerator (0-Yunkyeong Kang et al. 395




N-treated group J-treated group P value
mRS (score)
2) 4.8 ± 0.4 4.8 ± 0.4 4.7 ± 0.8 0.37
Sex (n)
Male 6 4 3 1.0
Female 0 2 3
Age (yrs) 65.5 ± 6.0 65.3 ± 18.0 66.8 ± 8.9 0.94
Previous illness 
(times)
1.2 ± 0.8 2.2 ± 1.2 2.3 ± 0.8 0.68
1) C h i  s q u a r e  t e s t  o r  t - t e s t
2) mRS, modified  Rankin Scale
4℃). Within 24 hrs, white blood cell (WBC), red blood cell 
(RBC), hemoglobin, hematocrit, platelet, mean corpuscular 
volume (MCV), mean corpuscular hemoglobin (MCH), and mean 
corpuscular hemoglobin concentration (MCHC) were analyzed 
in the blood samples using an automatic hematology analyzer 
(Hemavet 850, CDC Technology, USA). In addition, serum 
samples were prepared from blood samples in serum separator 
tubes (SST: BD vacutainer). SSTs were gently inverted 8-10 
times and allowed to clot for 30 minutes in vertical position. 
After coagulation, they were centrifuged at 3,000 g for 10 minutes, 
and stored in a refrigerator. Within 24 hrs, 11 biochemical 
markers including albumin, total protein, transferrin, triglyceride, 
high density lipoprotein (HDL), low density lipoprotein (LDL), 
total cholesterol, homocysteine, vitamin B12, sodium, and potassium 
were analyzed [14-22]. 
Medical records, e.g. demographic data, drug usage, and 
complications, were obtained to assess the health condition of 
patients. In addition, modified rankin scale (mRS) was assessed 
to classify disability. The scale of mRS runs from 0-6 (0, no 
symptoms; 1, no significant disability; 2, slight disability; 3, 
moderate disability; 4, moderately severe disability; 5, severe 
disability; 6, dead) [23]. The mRS was diagnosed by attending 
physicians for acute patients or trained community nurses for 
chronic patients. The scale raters referred to detail guidelines of 
Wilson  et al. [24] for elimination of diagnostic bias.
Analysis of malondialdehyde (MDA)
MDA was analyzed as MDA-thiobarbituric acid complex with 
HPLC/UVD [25]. In brief, standards of tetraethoxypropane (TEP: 
Sigma-Aldrich, Saint Louis, MO, USA) were serially diluted in 
40 % ethanol everyday, and 0.06, 0.125, 0.25, 0.5, and 1.0 μ㏖/L 
TEP were used for calibration. The TEP standards or 250 μl 
of plasma samples were treated with 25 μl of 0.2 % butylated 
hydroxytoluene (BHT: Sigma-Aldrich) in absolute ethanol, and 
followed by addition of 1 ml of 5 % trichloroacetic acid (TCA: 
Sigma-Aldrich). The mixtures were vortexed and centrifuged at 
4,000 g for 10 min. Five hundred μl of 0.6 % thiobarbituric acid 
(TBA: Sigma-Aldrich) was added to the 700 μl of deproteinized 
supernatant. The mixtures were vortexed and incubated for 45 
min at 90℃. After ice-cooling, the reaction mixtures were 
centrifuged at 4,000 g for 10 min. Four hundred μl of the 
supernatant of each sample was loaded to a HPLC-vial. 
HPLC/UVD system was composed of dual Younglin SP930D 
pumps (Younglin, Seoul, Korea), MIDAS COOL autosampler 
(Spark Holland, Emmen, The Netherlands), Shimadzu SPD-10A 
UV/VIS Detector (Shimadzu corporation, Tokyo, Japan), XTerra 
C18 column (5 μm, 4.6 × 250 mm, Waters, Wexford, Ireland), 
and CTS30 column oven (temperature at 40℃: Younglin). 
Mobile phase was made of 50 mM KH2PO4/K2HPO4  buffer (pH 
6.8) and methanol (58:42). Samples were analyzed with flow 
rate of 0.3 ml/min at 532 nm (injection volume, 200 μl)
Statistical analysis
Data were analyzed with SPSS (SPSS Inc, Chicago, IL, USA). 
Regression analyses were performed to study the enteral 
formula-induced changes in 20 biomarkers during the trials. Chi 
square test and Student’s t-tests were used to compare the 
characteristics between the N- and J-treated groups. Multivariate 
Analysis of Variance (MANOVA) was performed to compare 
effects of enteral formulas, N and J, on 20 biomarkers during 
the intervention. Paired t-test was used to compare the differences 
in caregiver burden or MDA levels between before and after 
the interventions. Differences were considered as statistically 
significant at P <0 . 0 5 .
Results
Long term trial
All patients in the long term trial were men, and their 
characteristics are shown in Table 2. Considering mRS-score, their 
disability is thought to be severe. Each subject was administered 
with almost same drugs such as antiepileptic drugs, antihypertensive 
drugs, anticoagulant drugs, diuretics, antiulcerants, and expectorants 
during the 6 month intervention. 
In a case of biomarker analyses, abnormalities in HDL, hemog-
lobin, hematocrit levels were somewhat improved, even though 
there wasn’t any significant change in the biomarkers during the 
study (Table 3). Concerning normality, HDL, sodium, RBC, 
hemoglobin, hematocrit and transferrin levels were slightly under 
the normal range, while MCV and vitamin B12 levels were higher 
than normal range for the intervention. Other biomarkers were 
within normal ranges. In addition, levels of MDA, an oxidative 
stress marker, were somewhat increased (before, 0.24 ± 0.02; 
after, 0.26 ± 0.02 µM, P>0 . 0 5 ) .  
Concerning SCQ among the caregivers, entire burden was 
significantly decreased due to the administration of the N. In 
addition, the subscale 2 score (satisfaction with one’s own 
performance as a caregiver) was also significantly decreased 
(Table 4). 396 Evaluation of enteral formulas
Table 3. Enteral formula N-induced changes on the 20 health and nutritional biomarkers in the long term trial
Item Normal value
Mean ± SD P 
value 0 2 months 4 months 6 months
Total protein (g/dL) 6.0-8.2 7.2 ± 0.8 7.1 ± 0.9 7.1 ± 0.6 7.3 ± 0.7 NS
1)
Albumin (g/dL) 3.4-5.6 3.4 ± 0.4 3.7 ± 0.3 3.6 ± 0.3 3.5 ± 0.3 NS
Cholesterol (mg/dL) ≤200 122.7 ± 34.1 130.5 ± 24.3 125.5 ± 17.1 134.3 ± 26.8 NS
Triglyceride (mg/dL) ≤150 49.0 ± 4.6 104.3 ± 103.9 86.3 ± 42.0 100.0 ± 61.8 NS
HDL (mg/dL) 40-60 38.0 ± 5.6 41.2 ± 11.7 41.7 ± 12.0 42.7 ± 17.6 NS
LDL (mg/dL) ≤130 72.3 ± 30.1 70.7 ± 21.4 69.7 ± 16.1 78.0 ± 26.0 NS
Sodium (mmol/L) 135-145 131.7 ± 4.2 134.2 ± 2.5 137.0 ± 3.6 134.2 ± 4.8 NS
Potassium (mmol/L) 3.5-5.5 4.5 ± 0.1 4.5 ± 0.2 4.4 ± 0.1 4.8 ± 0.3 NS
Homocysteine (μmol/L) ≤15.0 10.0 ± 2.4 8.8 ± 1.9 8.9 ± 1.4 10.0 ± 2.0 NS
WBC (1,000/ μL) 4-10 8.6 ± 7.6 6.5 ± 4.0 7.7 ± 6.5 6.4 ± 2.9 NS
RBC (million/ μL) 4.2-6.3 3.6 ± 0.5 3.9 ± 0.5 3.9 ± 0.4 4.0 ± 0.3 NS
Hemoglobin (g/dL) 12-17 11.5 ± 1.0 12.9 ± 1.4 12.7 ± 1.2 12.7 ± 1.1 NS
Hematocrit (%) 36-52 34.3 ± 2.9 38.2 ± 4.2 37.6 ± 3.1 38.6 ± 1.9 NS
MCV (fL) 79-96 96.0 ± 8.0 97.2 ± 6.2 97.5 ± 5.8 97.0 ± 7.0 NS
MCH (pg) 26-33 32.2 ± 3.7 32.9 ± 2.6 32.9 ± 2.4 31.9 ± 3.0 NS
MCHC (%) 32-37 33.5 ± 1.1 33.8 ± 1.0 33.7 ± 0.8 32.9 ± 1.5 NS
Platelet (1,000/μL) 150-450 238.3 ± 112.2 223.0 ± 75.8 201.3 ± 60.0 193.3 ± 50.5 NS
Transferrin (mg/dL) 200-360 186.0 ± 16.5 196.3 ± 32.5 187.0 ± 23.8 186.2 ± 16.0 NS
Vitamin B12  (pg/dL) 160-970 1329.6 ± 453.4 1329.5 ± 334.3 1128.8 ± 277.1 1266.2 ± 300.5 NS
MDA (μmol/L) 0.24 ± 0.02 0.25 ± 0.01 0.25 ± 0.02 0.26 ± 0.02 NS
1) NS,  Non-significant  time  dependent-effects  by  regression  analyses 
HDL, high density lipoprotein; LDL, low density lipoprotein; WBC, white blood cell; RBC, red blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; 
MCHC,  mean  corpuscular  hemoglobin  concentration;  MDA,  malondialdehyde
Table 4. Changes in SCQ scores of caregivers during the long term trial
1)
Mean
(standardized mean) SD Range
Before 
Subscale 1
2) 13.2 (1.89) 2.8 8-16
Subscale 2
2)  26.2 (2.18)  3.2 23-30
Subscale 3
2) 22.8 (2.85)
  3.8 20-30
Entire scale 62.2 (2.30) 6.4 52-69
After 
Subscale 1 11.4 (1.63) 3.3 7-15
Subscale 2 22.8 (1.90)
3) 3.5 16-26
Subscale 3 23.5 (2.94) 3.5 20-30
Entire scale 57.7 (2.14)
3) 7.8 46-68
1) Paired  t-test 
2) Subscale  1:  satisfaction  with  the  care  recipient
Subscale  2:  satisfaction  with  own  performance 
Subscale  3:  consequences  for  personal  life 
3) Significant  differences  between  before  and  after  trial,  P < 0.05
Fig. 1. Changes of hemoglobin levels in the short term trial. ○, the N-treated 
patients; ●, the J-treated patients (P < 0.05, difference between the 2 groups by 
MANOVA) Short term trial
Before performing a short term trial, we confirmed that there 
were no characteristic differences between two groups, who were 
ready to formula N or J (Table 2). One male patient among the 
N-treated group had severe stomach problems for several days 
during the trial, thus, his data of biomarkers were excluded. The 
characteristic differences between the N and J groups were not 
significant without him.
In the N-treated group, 19 biomarker levels were not 
significantly different between before and after intervention. 
Nutritional status from 19 biomarkers was maintained in normal 
during the study, except triglyceride, RBC, hemoglobin and 
hematocrit. Similarly, nutritional status of J-treated group was 
generally normal except triglyceride, HDL, RBC, hemoglobin, 
hematocrit, and vitamin B12 levels during the intervention. 
Finally, there was no significant difference in most of the 
analyzed biomarkers between the 2 groups (Table 5). Only 
hemoglobin levels were significantly improved more in the 
N-treated group than the J-treated group (P= 0.02, Table 5; Fig. 1).
We found that MDA levels were decreased for the treatment Yunkyeong Kang et al. 397
Table 5. Enteral formula N and J-induced changes in the 20 health and nutritional biomarkers during the short term trial
Item Normal
value
N-treated group J-treated group P
Value 0 Day 4 Day 7 Day 14 0 Day 4 Day 7 Day 14
Total protein (g/dL) 6.0-8.2 7.4 ± 0.2 7.3 ± 0.7 7.5 ± 0.6 7.3 ± 0.4 6.8 ± 0.6 6.9 ± 0.2 6.9 ± 0.4 6.9 ± 0.3 NS
1)
Albumin (g/dL) 3.4-5.6 3.7 ± 0.1 3.8 ± 0.2 3.8 ± 0.2 3.8 ± 0.3 3.7 ± 0.6 3.7 ± 0.4 3.7 ± 0.5 3.8 ± 0.5 NS
Cholesterol (mg/dL) ≤200 154.0 ± 13.9 155.2 ± 26.9 159.0 ± 28.5 166.2 ± 38.8 164.7 ± 31.5 163.3 ± 28.6 160.0 ± 28.5 166.8 ± 26.1 NS
Triglyceride (mg/dL) ≤150 120.0 ± 62.3 155.0 ± 71.2 172.4 ± 90.3 155.4 ± 85.8 139.8 ± 96.4 177.7 ± 102.6 149.5 ± 69.8 147.2 ± 79.8 NS
HDL (mg/dL) 40-60 41.6 ± 10.0 40.0 ± 13.5 42.8 ± 14.5 44.0 ± 12.8 35.2 ± 2.7 32.7 ± 7.4 34.0 ± 6.7 36.3 ± 6.0 NS
LDL (mg/dL) ≤130 92.4 ± 14.3 87.8 ± 21.2 87.6 ± 21.9 94.8 ± 29.4 113.7 ± 27.1 104.7 ± 24.8 105.7 ± 26.0 108.7 ± 25.7 NS
Sodium (mmol/L) 135-145 135.8 ± 3.5 136.2 ± 4.1 137.0 ± 4.3 137.0 ± 3.5 138.5 ± 3.4 136.7 ± 3.8 136.3 ± 5.0 135.0 ± 4.6 NS
Potassium (mmol/L) 3.5-5.5 5.0 ± 0.9 4.7 ± 0.7 4.4 ± 0.2 4.1 ± 0.4 4.4 ± 0.7 4.3 ± 0.8 4.5 ± 0.7 4.6 ± 0.3 NS
Homocysteine (μmol/L) ≤15.0 10.6 ± 3.3 11.4 ± 2.7 11.0 ± 1.4 10.6 ± 3.7 8.6 ± 1.5 9.2 ± 2.9 9.5 ± 2.3 10.1 ± 1.9 NS
WBC (1,000/ μL) 4-10 6.2 ± 1.6 6.9 ± 3.6 6.6 ± 2.7 6.9 ± 2.4 6.5 ± 1.0 6.8 ± 2.5 8.4 ± 1.5 7.9 ± 3.4 NS
RBC (million/ μL) 4.2-6.3 3.9 ± 0.7 4.0 ± 0.7 4.1 ± 0.8 4.1 ± 0.7 3.9 ± 0.3 4.0 ± 0.3 3.9 ± 0.3 3.9 ± 0.3 NS
Hemoglobin (g/dL) 12-17 11.7 ± 2.2 11.9 ± 2.1 12.3 ± 2.3 12.2 ± 1.9 11.5 ± 1.2 11.9 ± 1.0 11.7 ± 1.2 11.8 ± 0.9 0.02
2)
Hematocrit (%) 36-52 35.5 ± 6.2 35.9 ± 5.6 37.0 ± 6.2 36.7 ± 5.0 35.5 ± 3.4 36.0 ± 2.8 35.6 ± 3.2 35.6 ± 2.7 NS
MCV (fL) 79-96 91.0 ± 3.7 90.7 ± 4.6 90.6 ± 4.0 90.8 ± 4.0 92.1 ± 3.5 91.1 ± 3.5 91.0 ± 3.2 90.5 ± 3.3 NS
MCH (pg) 26-33 29.8 ± 1.7 29.9 ± 1.6 30.0 ± 1.4 30.2 ± 1.7 29.9 ± 1.4 30.2 ± 1.2 30.0 ± 1.3 29.9 ± 0.8 NS
MCHC (%) 32-37 32.8 ± 0.8 32.9 ± 1.2 33.2 ± 1.1 33.3 ± 1.3 32.5 ± 0.9 33.1 ± 0.7 32.9 ± 0.9 33.0 ± 0.7 NS
Platelet (1,000/μL) 150-450 274.8 ± 75.2 261.0 ± 62.6 273.8 ± 49.5 299.8 ± 74.2 318.0 ± 43.1 262.8 ± 97.1 308.3 ± 74.1 323.8 ± 90.0 NS
Transferrin (mg/dL) 200-360 210.6 ± 32.8 215.2 ± 30.0 219.8 ± 40.2 216.4 ± 45.3 208.5 ± 32.0 211.7 ± 39.2 212.0 ± 39.4 216.0 ± 33.9 NS
Vitamin B12  (pg/dL) 160-970 783.9 ± 298.4 923.2 ± 317.0 959.6 ± 429.3 887.7 ± 391.3 940.6 ± 572.7 918.0 ± 587.0 1004.8 ± 769.5 1003.0 ± 714.4 NS
MDA (μmol/L) 0.22 ± 0.02 0.21 ± 0.02 0.19 ± 0.02 0.20 ± 0.02 0.21 ± 0.03 0.20 ± 0.03 0.19 ± 0.02 0.19 ± 0.02 0.07
1) NS,  Non  significant  difference  of  time  dependent  changes  on  20  biomarkers  between  N-treated  and  J-treated  groups
2) Significant  difference  between  two  groups,  P <0 . 0 5
HDL, high density lipoprotein; LDL, low density lipoprotein; WBC, white blood cell; RBC, red blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; 
MCHC,  mean  corpuscular  hemoglobin  concentration;  MDA,  malondialdehyde
Table 6. Changes in SCQ scores between family and paid caregivers during













2) 11.7 (1.67) 4.3 8-18 12.2 (1.74) 2.0 10-14
Subscale2 
2) 22.0 (1.84) 4.0 17-29 22.7 (1.89) 3.1 20-26
Subscale3 
2) 23.1  (2.89) 1.3 21-25 20.7  (2.59) 1.9 19-24
Entire scale 56.9 (2.11) 7.7 50-71 55.6 (2.06) 3.8 51-60
After 
Subscale1 11.7 (1.67) 4.3 8-19 12.8 (1.83) 1.1 11-14
Subscale2 23.9 (1.99) 3.4 20-30 24.2 (2.02) 3.4 19-28
Subscale3 22.9 (2.86)  2.3 20-26 21.8 (2.73)
3) 1.9 20-25
Entire scale 58.4 (2.16) 9.0 49-74 58.8 (2.18) 5.6 51-66
1) Paired  t-test 
2) Subscale  1:  satisfaction  with  the  care  recipient 
Subscale  2:  satisfaction  with  own  performance 
Subscale  3:  consequences  for  personal  life 
3) Significant  difference  between  before  and  after  the  trial,  P < 0.05
(before, 0.22 ± 0.03; after, 0.19 ± 0.02 μM, 0.05 < P <0 . 1 ) .  
However, there was no significant difference between effects of 
the N and J groups on MDA levels.
In case of SCQ analysis for their caregivers, we found that 
there was no significant difference in entire scale scores or 
subscale scores between the N and J groups. When we divided 
caregivers into two groups, i.e. family members and paid 
caregivers, there was a significant increase in subscale 3 score 
(consequences for personal life) in not family members (n = 7) 
but the paid caregivers (n = 5: P = 0.01: Table 6).
Discussion
Efficacy of enteral nutrition is considered as great concerns 
due to its increased use for stroke patients. Several studies 
examined the risks and benefits of enteral nutrition for long term. 
For example, enteral formulas containing low amount of selenium 
and copper have reported to cause selenium deficiency and 
hematological disorders, respectively [26,27]. However, other 
studies demonstrated the nutritional benefit and safety of enteral 
nutrition for long term in cancer, pancreatitis, cystic fibrosis, 
Crohn’s disease, and chronic or end stage of renal failure [28-32]. 
In a case of stroke patients, most of efficacy studies for enteral 
nutrition were shortly performed. In this study, we investigated 
efficacy of enteral formula N for long term in stroke patients. 
Total of 19 health and nutritional biomarkers were well 
maintained during the intervention. Particularly, abnormal 
hemoglobin and hematocrit levels became to be normal according 
to the enteral nutrition (Table 3). Thus, the enteral formula N 
may have a potential to improve anemia. In case of home-made 
enteral formulas, we can infer their inappropriate formulation, 
compared to the enteral formula N. However, there is a report 
that average nutrients composition of various kinds of gruels was 398 Evaluation of enteral formulas
appropriate [33]. Therefore, we suspect that insufficient calorie 
intakes cause malnutrition with the use of home-made enteral 
formulas, rather than formulation issues. Malnutrition can be 
caused by low calorie intakes in enteral nutrition via rice gruels 
(per 1 serving size), which have lower calories, compared to 
dietary reference intakes for Korean per meal [34].
On the other hand, we found that levels of MDA, an oxidative 
stress biomarker, were higher in the present chronic stroke 
patients than those in other normal people (our patients, 0.28
± 0.04 µM; Templar et al. [25]’s normal people, 0.11 ± 0.03 μ
M). During the 6 months, MDA levels were gradually increased, 
and it is consistent with previous studies that oxidative stress 
increases stroke progression [35]. 
In case of caregiver burden, the present SCQ results were 
similar to those of other Korean studies (standardized mean of 
entire scale, duration of stroke; our study, 2.2, 6.0 yrs; others, 
2.3, 3.4 yrs) [36]. However, the average of entire scale score 
in a Dutch study [13] is lower than that of Koreans (Dutch, 47.3; 
Korean, 59.9). This difference may come from lower mRS scores 
in the Dutch study than those in our Korean study (mRS of 
Dutch’s, approximately 3.0; Koreans’, 4.8). Thus, severe disability 
of patients may increase caregiver-burden. In another study of 
dementia patients, Korean and Korean-American caregivers had 
higher levels of burden, depression, and anxiety than whites, 
because of social difference, therefore, not only mRS score but 
also social difference may causes the caregiver-burden variance 
[37]. In addition, entire scale and subscale 2 (satisfaction with 
one’s own performance as a caregiver) were clearly reduced by 
the N treatment (Table 4). Considering characteristics of 
‘subscale 2’, we suspect that the enteral formula N induces 
improvement of caregiver-burden from the satisfaction, which 
they provide adequately to their patients. As most of commercial 
enteral formulas have been used with recommendation of hospital 
experts, e.g. doctors, nurses and nutritionists, during patients’ 
hospitalization (from our unpublished data), the hospital experts’ 
recommendation for formulas is considered to be effective for 
the caregivers’ decision or satisfaction of the formulas. 
In the short term study, we examined whether two commercial 
enteral formulas have equal nutritional efficacy, even they are 
different in formulations and prices: Price of N is approximately 
2 folds lower than J. The results of the short term study showed 
that both of commercial enteral formulas were somewhat useful 
to maintain health and nutritional state of acute stroke patients, 
even though any biomarker level didn’t show a significant change 
during the administration. Most of biomarkers didn’t show any 
difference between the 2 enteral formulas (Table 5). Moreover, 
improvement of hemoglobin level was better in the N-treatment 
than that in the J-treatment (Fig. 1). In comparison of formulations, 
the enteral formula N has 3 fold higher amount of taurine than 
the enteral formula J (Table 1). Sirdah et al. [38] proved that 
addition of oral taurine (1,000 mg/day) enhances the RBC, 
hemoglobin, and ferritin levels in oral iron treated iron-deficiency 
anemia group due to its antioxidant effects. Therefore, we speculate 
that high amount of taurine may be related to improvement of 
the hemoglobin levels (Fig. 1). 
Concerning MDA changes, the short term study showed 
decrease in MDA levels during the intervention, while the long 
term trial did not. As acute stroke patients can be transiently 
recovered, compared to chronic patients, the changed MDA levels 
in the short term trial may come from interaction between 
characteristics of acute stroke and administration of enteral 
nutrition N.
In case of life quality, we found that there were no differences 
in caregiver-burden between N-treated and J-treated groups. In 
addition, there was heavier burden in subscale 3, i.e. consequences 
for personal life, among the paid caregivers than family caregivers 
(Table 6). The paid caregivers’ quality of life can directly 
influence care of the patients. In addition, social need for the 
paid caregivers is getting more increased. Thus, urgent and 
various ways, e.g. caregivers’ well being, should be prepared 
to reduce burden of job stress particularly for the paid caregivers.
In conclusion, our study showed that long term usage of 
commercial enteral nutrition, N, is somewhat effective to 
maintain nutritional state, particularly anemia-related biomarkers, 
in dysphagic stroke patients. In addition, the enteral formula N 
reduces the burden of caregivers with satisfaction of their care 
activity. Moreover, we evaluate that eneteral formula N has equal 
nutritional efficacy compared to the formula J, despite of their 
different prices in the short term trial. 
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